logo-loader
NASDAQ:RDHL

RedHill Biopharma Ltd

Receive alerts
Market:
NASDAQ
Price
0.51 USD
Day Change
6.75%
Market Cap:
$15.21 m
52 weeks high
4.91
52 weeks low
0.27

In brief

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Redhill's key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Snapshot

  • RedHill Biopharma says opaganib proposed mechanism of action not impacted by spike protein mutations, including Omicron mutations; provides update on regulatory submissions for opaganib
  • RedHill Biopharma shows strong inhibition by opaganib of the coronavirus Delta variant